The Influenza Vaccine Market is projected to grow from USD 9.02 billion in 2025 to USD 18.02 billion by 2034, at a CAGR of 7.97%. Growth is driven by pandemic preparedness, technological innovations, and global immunization efforts. North America leads, with Asia-Pacific witnessing the fastest expansion.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Influenza Vaccine Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Influenza Vaccine Market Revenue and Volume Forecast, by Vaccine Type
8.1.1. Quadrivalent
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Trivalent
8.1.2.1. Market Revenue and Volume Forecast
9.1. Influenza Vaccine Market Revenue and Volume Forecast, by Technology
9.1.1. Egg-based
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Cell culture
9.1.2.1. Market Revenue and Volume Forecast
10.1. Influenza Vaccine Market Revenue and Volume Forecast, by Age Group
10.1.1. Pediatric
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Adult
10.1.2.1. Market Revenue and Volume Forecast
11.1. Influenza Vaccine Market Revenue and Volume Forecast, by Route of Administration
11.1.1. Injection
11.1.1.1. Market Revenue and Volume Forecast
11.1.2. Nasal Spray
11.1.2.1. Market Revenue and Volume Forecast
12.1. North America
12.1.1. Market Revenue and Volume Forecast, by Vaccine Type
12.1.2. Market Revenue and Volume Forecast, by Technology
12.1.3. Market Revenue and Volume Forecast, by Age Group
12.1.4. Market Revenue and Volume Forecast, by Route of Administration
12.1.5. U.S.
12.1.5.1. Market Revenue and Volume Forecast, by Vaccine Type
12.1.5.2. Market Revenue and Volume Forecast, by Technology
12.1.5.3. Market Revenue and Volume Forecast, by Age Group
12.1.5.4. Market Revenue and Volume Forecast, by Route of Administration
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Volume Forecast, by Vaccine Type
12.1.6.2. Market Revenue and Volume Forecast, by Technology
12.1.6.3. Market Revenue and Volume Forecast, by Age Group
12.1.6.4. Market Revenue and Volume Forecast, by Route of Administration
12.2. Europe
12.2.1. Market Revenue and Volume Forecast, by Vaccine Type
12.2.2. Market Revenue and Volume Forecast, by Technology
12.2.3. Market Revenue and Volume Forecast, by Age Group
12.2.4. Market Revenue and Volume Forecast, by Route of Administration
12.2.5. UK
12.2.5.1. Market Revenue and Volume Forecast, by Vaccine Type
12.2.5.2. Market Revenue and Volume Forecast, by Technology
12.2.5.3. Market Revenue and Volume Forecast, by Age Group
12.2.5.4. Market Revenue and Volume Forecast, by Route of Administration
12.2.6. Germany
12.2.6.1. Market Revenue and Volume Forecast, by Vaccine Type
12.2.6.2. Market Revenue and Volume Forecast, by Technology
12.2.6.3. Market Revenue and Volume Forecast, by Age Group
12.2.6.4. Market Revenue and Volume Forecast, by Route of Administration
12.2.7. France
12.2.7.1. Market Revenue and Volume Forecast, by Vaccine Type
12.2.7.2. Market Revenue and Volume Forecast, by Technology
12.2.7.3. Market Revenue and Volume Forecast, by Age Group
12.2.7.4. Market Revenue and Volume Forecast, by Route of Administration
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Volume Forecast, by Vaccine Type
12.2.8.2. Market Revenue and Volume Forecast, by Technology
12.2.8.3. Market Revenue and Volume Forecast, by Age Group
12.2.8.4. Market Revenue and Volume Forecast, by Route of Administration
12.3. APAC
12.3.1. Market Revenue and Volume Forecast, by Vaccine Type
12.3.2. Market Revenue and Volume Forecast, by Technology
12.3.3. Market Revenue and Volume Forecast, by Age Group
12.3.4. Market Revenue and Volume Forecast, by Route of Administration
12.3.5. India
12.3.5.1. Market Revenue and Volume Forecast, by Vaccine Type
12.3.5.2. Market Revenue and Volume Forecast, by Technology
12.3.5.3. Market Revenue and Volume Forecast, by Age Group
12.3.5.4. Market Revenue and Volume Forecast, by Route of Administration
12.3.6. China
12.3.6.1. Market Revenue and Volume Forecast, by Vaccine Type
12.3.6.2. Market Revenue and Volume Forecast, by Technology
12.3.6.3. Market Revenue and Volume Forecast, by Age Group
12.3.6.4. Market Revenue and Volume Forecast, by Route of Administration
12.3.7. Japan
12.3.7.1. Market Revenue and Volume Forecast, by Vaccine Type
12.3.7.2. Market Revenue and Volume Forecast, by Technology
12.3.7.3. Market Revenue and Volume Forecast, by Age Group
12.3.7.4. Market Revenue and Volume Forecast, by Route of Administration
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Volume Forecast, by Vaccine Type
12.3.8.2. Market Revenue and Volume Forecast, by Technology
12.3.8.3. Market Revenue and Volume Forecast, by Age Group
12.3.8.4. Market Revenue and Volume Forecast, by Route of Administration
12.4. MEA
12.4.1. Market Revenue and Volume Forecast, by Vaccine Type
12.4.2. Market Revenue and Volume Forecast, by Technology
12.4.3. Market Revenue and Volume Forecast, by Age Group
12.4.4. Market Revenue and Volume Forecast, by Route of Administration
12.4.5. GCC
12.4.5.1. Market Revenue and Volume Forecast, by Vaccine Type
12.4.5.2. Market Revenue and Volume Forecast, by Technology
12.4.5.3. Market Revenue and Volume Forecast, by Age Group
12.4.5.4. Market Revenue and Volume Forecast, by Route of Administration
12.4.6. North Africa
12.4.6.1. Market Revenue and Volume Forecast, by Vaccine Type
12.4.6.2. Market Revenue and Volume Forecast, by Technology
12.4.6.3. Market Revenue and Volume Forecast, by Age Group
12.4.6.4. Market Revenue and Volume Forecast, by Route of Administration
12.4.7. South Africa
12.4.7.1. Market Revenue and Volume Forecast, by Vaccine Type
12.4.7.2. Market Revenue and Volume Forecast, by Technology
12.4.7.3. Market Revenue and Volume Forecast, by Age Group
12.4.7.4. Market Revenue and Volume Forecast, by Route of Administration
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Volume Forecast, by Vaccine Type
12.4.8.2. Market Revenue and Volume Forecast, by Technology
12.4.8.3. Market Revenue and Volume Forecast, by Age Group
12.4.8.4. Market Revenue and Volume Forecast, by Route of Administration
12.5. Latin America
12.5.1. Market Revenue and Volume Forecast, by Vaccine Type
12.5.2. Market Revenue and Volume Forecast, by Technology
12.5.3. Market Revenue and Volume Forecast, by Age Group
12.5.4. Market Revenue and Volume Forecast, by Route of Administration
12.5.5. Brazil
12.5.5.1. Market Revenue and Volume Forecast, by Vaccine Type
12.5.5.2. Market Revenue and Volume Forecast, by Technology
12.5.5.3. Market Revenue and Volume Forecast, by Age Group
12.5.5.4. Market Revenue and Volume Forecast, by Route of Administration
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Volume Forecast, by Vaccine Type
12.5.6.2. Market Revenue and Volume Forecast, by Technology
12.5.6.3. Market Revenue and Volume Forecast, by Age Group
12.5.6.4. Market Revenue and Volume Forecast, by Route of Administration
13.1. Sanofi Pasteur
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. GlaxoSmithKline plc (GSK)
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Seqirus (a CSL Limited Company)
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Pfizer Inc.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. AstraZeneca
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. BiondVax Pharmaceuticals Ltd.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Novavax, Inc.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Bharat Biotech
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Johnson & Johnson
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. MedImmune, LLC (AstraZeneca)
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description